- Update of a phase II, multicenter clinical trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC.Yan, Jin; Han, Yunwei; Zhang, Li; Jin, Yongdong; Sun, HaoAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- CPGJ602 plus mFOLFOX6 as first-line treatment for patients with KRAS/NRAS/BRAF wild-type metastatic colorectal cancer: A randomized phase II study.Xu, Jianming; Cao, Bangwei; Gu, Kangsheng; Bai, Yuxian; Li, Wei; Zhang, Jingdong; Liu, Caigang; Niu, Zuoxing; Zhang, Liangming; Zhong, Haijun; Luo, Suxia; Zhou, Jian-Wei; Liu, Tianshu; Gu, Yanhong; Lin, Jingguan; Deng, Yanhong; Chen, Chuangqi; Li, Yunfeng; Yang, Xiuli; Li, BihuiAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trialArinilda Campos, Bragagnoli; Raphael L. C., Araujo; Mauricio Wagner, Ferraz; Lucas Vieira, dos Santos; Kathia Cristina, Abdalla; Fabiana, Comar; Florinda Almeida, Santos; Marco Antonio, Oliveira; José Barreto Campello, Carvalheira; Flávio Mavigner, Cárcano; João Paulo, da Silveira Nogueira LimaBritish Journal of Cancer, 2021, 124(6): 1072-1078.
会议论文
SHR-1701 in combination with BP102 and XELOX as first-line (1L) treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Data from a phase II/III study
10阅读
